These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 31463696)

  • 21. Tenascin-C is involved in promotion of cancer stemness via the Akt/HIF1ɑ axis in esophageal squamous cell carcinoma.
    Yang Z; Zhang C; Feng Y; Qi W; Cui Y; Xuan Y
    Exp Mol Pathol; 2019 Aug; 109():104239. PubMed ID: 30904401
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and prognostic role of annexin A2 in multiple myeloma.
    Seckinger A; Meissner T; Moreaux J; Depeweg D; Hillengass J; Hose K; Rème T; Rösen-Wolff A; Jauch A; Schnettler R; Ewerbeck V; Goldschmidt H; Klein B; Hose D
    Blood; 2012 Aug; 120(5):1087-94. PubMed ID: 22705595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stromal Annexin A2 expression is predictive of decreased survival in pancreatic cancer.
    Murphy AG; Foley K; Rucki AA; Xia T; Jaffee EM; Huang CY; Zheng L
    Oncotarget; 2017 Dec; 8(63):106405-106414. PubMed ID: 29290958
    [TBL] [Abstract][Full Text] [Related]  

  • 24.
    Wang Z; Jiang C; Pang L; Jia W; Wang C; Gao X; Zhang X; Dang H; Ren Y
    Biomark Med; 2021 Jan; 15(1):57-67. PubMed ID: 33315468
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical and prognostic role of annexin A2 in adamantinomatous craniopharyngioma.
    Wang Y; Deng J; Guo G; Tong A; Peng X; Chen H; Xu J; Liu Y; You C; Zhou L
    J Neurooncol; 2017 Jan; 131(1):21-29. PubMed ID: 27640198
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intracellular annexin A2 regulates NF-κB signaling by binding to the p50 subunit: implications for gemcitabine resistance in pancreatic cancer.
    Jung H; Kim JS; Kim WK; Oh KJ; Kim JM; Lee HJ; Han BS; Kim DS; Seo YS; Lee SC; Park SG; Bae KH
    Cell Death Dis; 2015 Jan; 6(1):e1606. PubMed ID: 25611381
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative proteomics identify Tenascin-C as a promoter of lung cancer progression and contributor to a signature prognostic of patient survival.
    Gocheva V; Naba A; Bhutkar A; Guardia T; Miller KM; Li CM; Dayton TL; Sanchez-Rivera FJ; Kim-Kiselak C; Jailkhani N; Winslow MM; Del Rosario A; Hynes RO; Jacks T
    Proc Natl Acad Sci U S A; 2017 Jul; 114(28):E5625-E5634. PubMed ID: 28652369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
    Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
    J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression and clinical significance of annexin A2 and human epididymis protein 4 in endometrial carcinoma.
    Deng L; Gao Y; Li X; Cai M; Wang H; Zhuang H; Tan M; Liu S; Hao Y; Lin B
    J Exp Clin Cancer Res; 2015 Sep; 34(1):96. PubMed ID: 26362938
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Up-regulation of annexin A2 expression predicates advanced clinicopathological features and poor prognosis in hepatocellular carcinoma.
    Zhang H; Yao M; Wu W; Qiu L; Sai W; Yang J; Zheng W; Huang J; Yao D
    Tumour Biol; 2015 Dec; 36(12):9373-83. PubMed ID: 26109000
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation of expression levels of ANXA2, PGAM1, and CALR with glioma grade and prognosis.
    Gao H; Yu B; Yan Y; Shen J; Zhao S; Zhu J; Qin W; Gao Y
    J Neurosurg; 2013 Apr; 118(4):846-53. PubMed ID: 23082878
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biological Effect and Mechanism of the miR-23b-3p/ANXA2 Axis in Pancreatic Ductal Adenocarcinoma.
    Wei DM; Dang YW; Feng ZB; Liang L; Zhang L; Tang RX; Chen ZM; Yu Q; Wei YC; Luo DZ; Chen G
    Cell Physiol Biochem; 2018; 50(3):823-840. PubMed ID: 30355917
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tenascin C is a prognostic determinant and potential cancer-associated fibroblasts marker for breast ductal carcinoma.
    Yang Z; Ni W; Cui C; Fang L; Xuan Y
    Exp Mol Pathol; 2017 Apr; 102(2):262-267. PubMed ID: 28223108
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic features of Annexin A2 expression in prostate cancer.
    Tan SH; Young D; Chen Y; Kuo HC; Srinivasan A; Dobi A; Petrovics G; Cullen J; Mcleod DG; Rosner IL; Srivastava S; Sesterhenn IA
    Pathology; 2021 Feb; 53(2):205-213. PubMed ID: 32967771
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tenascin-C as a prognostic determinant of colorectal cancer through induction of epithelial-to-mesenchymal transition and proliferation.
    Yang Z; Zhang C; Qi W; Cui C; Cui Y; Xuan Y
    Exp Mol Pathol; 2018 Oct; 105(2):216-222. PubMed ID: 30170017
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The clinical significance of tenascin-C splice variant expression in chondrosarcoma.
    Ghert MA; Jung ST; Qi W; Harrelson JM; Erickson HP; Block JA; Scully SP
    Oncology; 2001; 61(4):306-14. PubMed ID: 11721178
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MIEN1, a novel interactor of Annexin A2, promotes tumor cell migration by enhancing AnxA2 cell surface expression.
    Kpetemey M; Dasgupta S; Rajendiran S; Das S; Gibbs LD; Shetty P; Gryczynski Z; Vishwanatha JK
    Mol Cancer; 2015 Aug; 14():156. PubMed ID: 26272794
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic and diagnostic significance of annexin A2 in colorectal cancer.
    Yang T; Peng H; Wang J; Yang J; Nice EC; Xie K; Huang C
    Colorectal Dis; 2013 Jul; 15(7):e373-81. PubMed ID: 23489866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Coexpression of ANXA2, SOD2 and HOXA13 predicts poor prognosis of esophageal squamous cell carcinoma.
    Ma RL; Shen LY; Chen KN
    Oncol Rep; 2014 May; 31(5):2157-64. PubMed ID: 24626613
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tenascin-C and fibronectin expression divide early stage tongue cancer into low- and high-risk groups.
    Sundquist E; Kauppila JH; Veijola J; Mroueh R; Lehenkari P; Laitinen S; Risteli J; Soini Y; Kosma VM; Sawazaki-Calone I; Macedo CC; Bloigu R; Coletta RD; Salo T
    Br J Cancer; 2017 Feb; 116(5):640-648. PubMed ID: 28095396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.